Malondialdehyde as a Useful Biomarker of Low Hand Grip Strength in Community-Dwelling Stroke Patients

Onchuma Mueangson¹, Parinya Vongvaivanichakul¹, Kornyok Kamdee¹, Chutima Jansakun¹, Wanatsanan Chulrik¹, Pongphan Pongpanitanont¹, Pornchai Sathirapanya²* and Warangkana Chunglok¹,*

¹ School of Allied Health Sciences and Research Institute for Health Sciences, Walailak University, Nakhon Si Thammarat 80161, Thailand; onchuma.mu@wu.ac.th (O.M.); parinya.vo@wu.ac.th (P.V.); kornyok.ka@wu.ac.th (K.K.); chutimaj65@gmail.com (C.J.); manatwanatsananmnt@gmail.com (W.C.); pongphan.po@wu.ac.th (P.P.)
² Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkla 90110, Thailand; sporncha@medicine.psu.ac.th
* Correspondence: cwarang@wu.ac.th; Tel: +66-7567-2681

Received: 30 September 2020; Accepted: 24 October 2020; Published: 28 October 2020

Abstract: The assessment of muscle strength by hand grip strength (HGS) is used to evaluate muscle weakness and wasting among stroke patients. This study aimed to investigate the association of oxidative stress/oxidative damage and inflammatory biomarkers with muscle strength and wasting, as evaluated by HGS, among community-dwelling post-stroke patients. The HGS of both paretic and non-paretic limbs was negatively associated with modified Rankin scale (mRS) values. The serum levels of catalase activity and malondialdehyde (MDA), and plasma tumor necrosis factor (TNF)-α levels were significantly increased in post-stroke patients compared with non-stroke controls. Further analysis highlighted that hydrogen peroxide was positively correlated with HGS in the paretic limbs. Interestingly, an elevated MDA level, excluding advanced age and high mRS, increased the risk of low HGS in the non-paretic limbs of stroke patients. This study suggests that there is a detrimental association between MDA and muscle strength and early muscle wasting among post-stroke patients. Hence, MDA is a potentially useful biomarker of muscle weakness and wasting in post-stroke patients living in the community.

Keywords: ischemic stroke; muscle strength; hydrogen peroxide; oxidative damage; inflammatory cytokines

1. Introduction

Strokes place a major burden on the health care system globally [1]. The most frequent impairment after stroke is hemiparesis, followed by dysarthria, visual disturbance, facial palsy, spasticity, imbalance, post-stroke pain or physical discomfort, and dysphagia. These conditions significantly affect stroke patients’ activities of daily living as well as their quality of life [2,3]. Changes in the size and strength of the skeletal muscles in both paretic and non-paretic limbs have been reported in post-stroke patients [4]. As early as 4 to 30 h after the onset of an acute ischemic stroke (IS), the number of motor units estimated in the hypothenar muscles of paretic limbs starts to decline compared with that in non-paretic limbs [5]. An ongoing reduction in the number of motor units, a disturbance in the motor unit firing intensity, and long-standing muscle denervation were observed in the paretic muscles in late-stage post-stroke subjects. These factors could contribute to muscle weakness and wasting [6,7]. Notably, muscle...
weakness has also been shown to appear in the non-paretic limbs within the first week after the onset of a stroke [8].

Hand grip strength (HGS) is widely accepted as a reliable measurement for whole-body muscle strength in healthy adults, as well as an indicator of muscle weakness and wasting after stroke [9–11]. The relative sustainability of the paretic side’s grip force was shown to be 20–30% lower than that of the non-paretic one at 2–4 weeks post-stroke, and the value gradually rose to a level comparable with that of the non-paretic side at 6 months post-stroke [12]. The HGS of the non-paretic hands in stroke patients was found to be obviously less than the HGS of the dominant hand in non-stroke controls [13]. Furthermore, the HGS on the non-paretic side has been shown to be positively associated with the competence of pulmonary function and respiratory muscle strength [14], functional improvement after rehabilitation [15], and the degree of independency, as evaluated by the Barthel index (BI) at hospital discharge [16] in late post-stroke patients. In contrast, the HGS of the paretic hand was negatively correlated with the stroke severity, as evaluated by the National Institutes of Health Stroke Scale (NIHSS) score, and the degree of disability, as assessed by the modified Rankin Scale (mRS) at discharge and 3 months after stroke occurrence [16]. Recently, the Asian Working Group for Sarcopenia (AWGS) 2019 suggested that a low HGS is one of the key measurements of “possible sarcopenia” used in primary or community health care services [17]. The Asian Working Group for Sarcopenia (AWGS) 2014 defined “sarcopenia” as age-related loss of muscle mass together with decreased muscle strength and/or loss of physical performance [18]. The term was used to describe the loss of muscle mass and functions related to various post-stroke illnesses and muscle disuse conditions [19,20].

Oxidative stress/oxidative damage and inflammation play roles in the pathogenesis of stroke-induced muscle weakness and eventual wasting and disability [21]. Most published articles reveal a correlation of oxidative stress/oxidative damage and inflammatory biomarkers, e.g., malondialdehyde (MDA), 4-hydroxy-2 (E)-nonenal (4-HNE), the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and the inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α with sarcopenia in older adults [22–24]. To date, only a few studies have investigated the correlations of the aforementioned biomarkers with muscle wasting in post-stroke patients [25]. A study reported that the presence of systemic inflammation determined by CRP is negatively associated with HGS and BI but positively associated with mRS [26]. Furthermore, another study reported that paretic muscles express significantly increased TNF-a mRNA levels compared with the non-paretic muscles of late IS patients, suggesting the presence of active inflammation in paretic muscles [27]. Therefore, this study aims to identify reliable biomarkers that correlate well with low HGS in community post-stroke patients. We propose that low HGS could be associated with higher levels of oxidative stress/oxidative damage biomarkers and inflammatory cytokines.

2. Materials and Methods

2.1. Study Participants

A total of 338 participants, comprised of 146 IS patients and 192 non-stroke controls, were enrolled in this community-based, cross-sectional study in January 2018 and December 2018. All participants were Buddhists and Muslims who lived in Thasala and Mueang Districts, Nakhon Si Thammarat, Thailand. We enrolled all IS patients who were (1) aged 45–95 years; (2) hemiparetic from first-ever stroke, as diagnosed by a computerized tomography (CT) scan and/or magnetic resonance imaging (MRI) within 24 h of symptom onset; (3) had ≥ 3 months of a stable medical condition post-stroke and received the same class of drug regimen; and (4) had spastic hypertonia in the hand muscles on the paretic side, as determined by a modified Ashworth Scale (MAS) score of < 3. Those with systemic inflammatory diseases, autoimmune diseases, renal or liver diseases, myocardial infarction, cancer, or thyroid diseases; those who were post-surgery within 60 days of enrollment; those unable to communicate well enough to complete the study process; and those that did not provide informed consent were excluded from the study. Non-stroke controls were individuals with no known serious
underlying diseases or physical disabilities who were selected from attendants to routine physical check-ups in the sub-district health promoting hospitals in the same areas as the stroke patients.

We used a matched study design (1:1) considering age (±4 years), gender, religion, and body mass index (BMI) (±2.5 units) to evaluate the significant differences between cases and controls. We enrolled the stroke patients and matched controls from non-stroke study participants consecutively.

Data collected included baseline characteristics of the study population from personal interviews by well-trained interviewers using specific questionnaires. The underlying cardiovascular risks based on primary care physician diagnoses in sub-district health promoting hospitals were identified.

The terms and medical conditions used in the current study were defined. BMI was calculated from weight in kilograms divided by height in meters squared (kg/m²) [28]. Adequate physical activity was defined based on participants’ self-reports as exercise ≥ 3 times per week for at least 30 min at a time. Hypertension was defined as a resting systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg or requirement for antihypertensive drugs [29]. Hyperlipidemia was diagnosed in individuals taking any antilipidemic drugs or acquiring one or more of the following blood lipid results: total cholesterol (TC) ≥ 200 mg/dL, low-density lipoprotein cholesterol (LDL-C) ≥ 130 mg/dL, high-density lipoprotein cholesterol (HDL-C) ≤ 40 mg/dL, or triglycerides (TG) ≥ 150 mg/dL [30]. Diabetes mellitus was taken as a fasting plasma glucose (FPG) ≥ 126 mg/dL or current use of glycemic control medication. Impaired fasting glucose was defined as fasting blood sugar (FBS) of 100–125 mg/dL [31]. Smoking was defined as smoking an average of ≥ 1 cigarette per day in the last 3 months. Alcohol beverage drinking was based on participants’ self-reports of drinking ≥ 100 mL of alcohol more than three times per week.

The research protocol was approved by the Walailak University ethics committee (16/037), and written informed consent was obtained from all participants.

2.2. Physical Measurement Tools

2.2.1. Barthel Index (BI)

Stroke patients were evaluated on their ability to perform fifteen tasks independently. These tasks included three main functions: self-care, continence of bowel and bladder, and mobility [32]. The scores were classified as 0–20, 21–60, 61–90, and 91–99, indicating total, severe, moderate, and slight dependency, respectively [33].

2.2.2. Modified Rankin Scale (mRS)

The stroke patients were interviewed about their ability to perform their daily activities. The mRS was used to evaluate the degree of disability in doing daily activities in this study. Scores of 0–2 indicated no symptoms to a slight disability, while scores of 3–5 indicated moderate to severe disability, and a score of 6 indicated that the patient was dead [34].

2.2.3. Hand Grip Strength (HGS)

HGS (kilograms) was measured using a dynamometer (Takei TKK 5001, Takei Scientific Instruments Co. Ltd., Tokyo, Japan) [35]. While in standing or sitting upright positions, participants had each arm in flexion and did not contact the trunk. Then, they were asked to perform maximal voluntary hand muscle contractions with the dynamometer twice, 2 min apart to avoid muscle fatigue, with each hand. Non-stroke controls were asked to perform the maximal force contractions with the dominant hand. The term “HGS” was the mean values of hand grip strength, and the term “low HGS” was defined as HGS of lower than 26 kg for men and 18 kg for women [18].

2.3. Blood Sample Processing

Ten milliliters of fasting venous blood was only once at admission collected from each participant and then centrifuged at 1200×g for 5 min at 25 °C. Serum and plasma were separated and stored at
−80 °C. The obtained serum was assessed for levels of fasting blood sugar (FBS), lipid profile, and oxidative stress/oxidative damage markers (catalase (CAT), superoxide dismutase (SOD), hydrogen peroxide, and MDA). Additionally, plasma from ethylenediaminetetraacetic acid (EDTA) blood samples was assessed for inflammatory cytokines (TNF-α and IL-6). All biomarkers and cytokines were analyzed within 2 weeks after collection.

2.4. Measurement of Biomarkers

2.4.1. Metabolic Profiles

FBS, TG, TC, LDL-c, and HDL-c were measured by an automated analyzer (Beckman Coulter, Brea, CA, USA).

2.4.2. Oxidative Stress/Oxidative Damage

SOD and CAT activities in the collected serum were determined by a commercial kit (Sigma-Aldrich, St. Louis, MO, USA), and the hydrogen peroxide concentration was determined by the commercial Pierce Quantitative Peroxide Assay kit (Pierce Biotechnology, Rockford, IL, USA), following the manufacturer’s instructions. The MDA level was determined by the concentration of thiobarbituric acid reactive substance (TBARS) in serum based on MDA and the thiobarbituric acid reaction, as previously described [36]. Briefly, serum was added to sodium dodecyl sulfate and thiobarbituric acid under acidic conditions, and then the reaction mixture was heated at 95 °C for 60 min. After cooling with tap water, butanol:pyridine (15:1) solution was added to the mixture, vortexed, and centrifuged at 2000×g for 10 min. The formation of TBARS was measured by using a microplate reader (BioTek Instruments Inc., Winooski, VT, USA) at 532 nm.

2.4.3. Inflammatory Cytokines

IL-6 and TNF-α levels were measured using ELISA kits (BioLegend, San Diego, CA, USA) in accordance with the manufacturer’s instructions. Plasma was prepared as undiluted samples. Serial dilutions of recombinant IL-6 and TNF-α standards were included on each plate to determine plasma IL-6 and TNF-α concentrations in the samples. Then, plasma IL-6 and TNF-α concentrations in samples were measured by a microplate reader at 450 nm, and the values are reported in pg/mL.

2.5. Statistical Analyses

The software package used to analyze the collected data was SPSS (PASW Statistic, version 16, Chicago, IL, USA). The differences in variables between stroke patients and non-stroke controls were evaluated by chi-square tests, independent t-tests, and the Mann–Whitney U test. The presence of a normal distribution was assessed using the Kolmogorov–Smirnov test. Categorical variables are presented as proportions, while continuous variables are reported as either means ± standard deviation (SD) or medians (interquartile range (IQR). To identify significant associations between clinical variables and HGS in stroke participants, multiple linear regression and multiple logistic regression analyses were performed, and p < 0.05 indicated significance.

3. Results

3.1. Study Population

Twenty-five cases in the patient group were excluded due to a lack of matched controls, while another thirty cases were subsequently excluded because of an inadequate volume of serum obtained for biomarker assessments. Therefore, 91 patients were deemed fit for statistical analysis.

Stroke patients had higher incidences of hypertension (p = 0.005), hyperlipidemia (p = 0.002), and diabetes mellitus (p = 0.001) than controls. The mean (± SD) BI value in stroke patients was 85.33 (±25.73), and the majority of them (71.43%) showed slight dependency and disability (mRs
0–2). TC and LDL-c concentrations were significantly lower in stroke patients compared with controls (both \( p < 0.0001 \)). This may be an effect of the cholesterol-lowering drug used in stroke patients. Interestingly, the levels of MDA and TNF-\( \alpha \) were significantly higher in stroke patients (\( p = 0.022 \) and 0.004, respectively) (Table 1).

### Table 1. Baseline characteristics of non-stroke controls and stroke patients.

| Variables                      | Stroke Patients \( (n = 91) \) | Non-Stroke Controls \( (n = 91) \) | \( p \)-Value |
|--------------------------------|---------------------------------|-----------------------------------|--------------|
| Age (years)                    | 69 (14)                         | 68 (13)                           | 0.916        |
| Gender, \( n \) (%)           |                                 |                                   | 1            |
| Male                           | 59 (64.84)                      | 59 (64.84)                        |              |
| Female                         | 32 (35.16)                      | 32 (35.16)                        |              |
| Body mass index, kg/m\(^2\)   | 22.51 ± 3.12                    | 22.62 ± 3.53                      | 0.826        |
| Physical activity, \( n \) (%)|                                 |                                   | 0.432        |
| No                             | 28 (30.77)                      | 33 (36.26)                        |              |
| Yes                            | 63 (69.23)                      | 58 (63.74)                        |              |
| Vascular risk factors, \( n \) (%)|                                 |                                   |              |
| Hypertension                   | 74 (81.32)                      | 57 (62.64)                        | 0.005 \(^b\) |
| Hyperlipidemia                 | 73 (80.22)                      | 54 (59.34)                        | 0.002 \(^b\) |
| Diabetes mellitus              | 26 (28.57)                      | 8 (8.79)                          | 0.001 \(^b\) |
| Impaired fasting glucose       | 9 (9.89)                        | 16 (17.58)                        | 0.132        |
| Smoking status, \( n \) (%)    |                                 |                                   | 0.581        |
| No                             | 71 (78.02)                      | 74 (81.32)                        |              |
| Yes                            | 20 (21.98)                      | 17 (18.68)                        |              |
| Alcohol drinking, \( n \) (%) |                                 |                                   | 0.155        |
| No                             | 84 (92.31)                      | 78 (85.71)                        |              |
| Yes                            | 7 (7.69)                        | 13 (14.29)                        |              |
| Barthel index, mean ± SD       | 85.33 ± 25.73                   | 100.00 ± 0.00                     | <0.0001 \(^a\) |
| 0–20, \( n \) (%)              | 5 (5.49)                        | 0 (0.00)                          |              |
| 21–60, \( n \) (%)             | 13 (14.28)                      | 0 (0.00)                          |              |
| 61–90, \( n \) (%)             | 10 (10.99)                      | 0 (0.00)                          |              |
| 91–99, \( n \) (%)             | 9 (9.89)                        | 0 (0.00)                          |              |
| 100, (%)                       | 54 (59.34)                      | 91 (100.00)                       |              |
| Modified Rankin Scale, mean ± SD | 1.73 ± 1.28                  | N/A                               | N/A          |
| (0–2), \( n \) (%)             | 65 (71.43)                      | N/A                               | N/A          |
| (3–5), \( n \) (%)             | 26 (28.57)                      | N/A                               | N/A          |
| Biochemical parameters         |                                 |                                   |              |
| FBS (mg/dL)                    | 95.00 (18.25)                   | 93.00 (14.25)                     | 0.224        |
| TG (mg/dL)                     | 119.00 (89.25)                  | 130.00 (67.50)                    | 0.544        |
| TC (mg/dL)                     | 164.28 ± 41.50                  | 203.20 ± 37.93                    | <0.0001 \(^c\) |
| LDL-c (mg/dL)                  | 98.50 (41.25)                   | 128.80 (48.10)                    | <0.0001 \(^a\) |
| HDL-c (mg/dL)                  | 50.16 ± 12.74                   | 49.67 ± 12.18                     | 0.663        |
Table 1. Cont.

| Variables                      | Stroke Patients | Non-Stroke Controls | p-Value |
|--------------------------------|-----------------|--------------------|---------|
|                                | (n = 91)        | (n = 91)           |         |
| CAT (U/L)                      | 132.21 (98.61)  | 76.85 (96.80)      | <0.0001a|
| SOD (U/L)                      | 3149.00 (2350.38)| 3791.42 (2716.27) | <0.0001a|
| Hydrogen peroxide (µM)         | 14.40 (7.75)    | 18.76 (8.88)       | 0.064   |
| MDA (µM)                       | 7.05 (3.49)     | 5.98 (5.68)        | 0.022a  |
| TNF-α (pg/mL)                  | 37.93 (58.63)   | 22.17 (21.69)      | 0.004a  |
| IL-6 (pg/mL)                   | 27.30 (71.94)   | 42.51 (88.36)      | 0.144   |

CAT, catalase; FBS, fasting blood sugar; HDL-c, high-density lipoprotein cholesterol; IL-6, interleukin 6; LDL-c, low-density lipoprotein cholesterol; MDA, malondialdehyde; N/A, not available; SOD, superoxide dismutase; TC, total cholesterol; TG, triglyceride; TNF-α, tumor necrosis factor-alpha. a p < 0.05, Mann–Whitney U test, b p < 0.05, chi-square test, c p < 0.05, independent t-test.

3.2. Hand Grip Strength of Paretic and Non-Paretic Limbs in Stroke Patients

The overall mean HGS of paretic limbs in stroke patients was 13.49 ± 11.04 kg. However, the mean HGS values of males and females were 16.62 ± 11.53 and 7.71 ± 7.19 kg, respectively—lower than the cut-off values for both genders (<26 kg (male), and <18 kg (female).

The mean HGS values of non-paretic limbs and dominant hands of the two study groups did not differ. Male stroke patients had significantly lower HGS of non-paretic limbs than dominant hands of non-stroke controls (p = 0.048). However, the number of stroke patients with low HGS was 57 (62.64%), which was not different from the number of controls (50 subjects, 54.95%) (Table 2).

Table 2. Hand grip strength of paretic and non-paretic limbs in stroke patients and dominant hands in non-stroke controls.

| Clinical Variables             | Stroke Patients | Non-Stroke Controls | p-Value |
|--------------------------------|-----------------|--------------------|---------|
|                                | n (%)           | Mean ± SD          | n (%)   | Mean ± SD |         |
| Hand grip strength, kg (paretic-limbs) |                 |                    |         |
| Total                          | 91 (100.00)     | 13.49 ± 11.04      | N/A     | N/A       | N/A     |
| Male                           | 59 (67.53)      | 16.62 ± 11.53      | N/A     | N/A       | N/A     |
| Female                         | 32 (32.47)      | 7.71 ± 7.19        | N/A     | N/A       | N/A     |
| Hand grip strength, kg (non-paretic limbs/dominant hands) |                    |                    |         |
| Total                          | 91 (100.00)     | 21.24 ± 8.61       | 91 (100.00) | 23.05 ± 8.15 | 0.148 |
| Male                           | 59 (67.53)      | 24.62 ± 7.92       | 59 (64.83) | 26.75 ± 7.05 | 0.127 |
| Female                         | 32 (32.47)      | 15.01 ± 5.87       | 32 (35.17) | 16.23 ± 5.08 | 0.380 |
| Low hand grip strength, kg (non-paretic limbs/dominant hands) |                    |                    |         |
| Total                          | 57 (62.64)      | 16.47 ± 5.58       | 50 (54.95) | 17.94 ± 5.14 | 0.212 |
| Male                           | 35 (38.46)      | 19.22 ± 4.50       | 29 (31.87) | 21.29 ± 3.33 | 0.048 |
| Female                         | 22 (24.18)      | 11.99 ± 4.11       | 21 (23.08) | 13.31 ± 3.24 | 0.895 |

N/A, not available. * p < 0.05, independent t-test.
3.3. The Impact of Hydrogen Peroxide on HGS in Paretic Limbs of Stroke Patients

The multiple linear regression analysis was used to analyze age, gender, BMI, mRS, CAT, SOD, hydrogen peroxide, MDA, TNF-α, and IL-6 for factor independently correlated with HGS in non-paretic and paretic limbs of stroke patients. Our results showed that age (beta = −0.346; p < 0.0001), female (beta = −0.392; p < 0.0001), and mRS (beta = −0.404; p < 0.0001) were negatively correlated with HGS of non-paretic limbs. For paretic limbs, HGS was negatively correlated with female (beta = −0.202; p < 0.014) and mRS (beta = −0.627; p < 0.0001). Nonetheless, HGS of paretic limbs was found positively correlated with the level of hydrogen peroxide (beta = 0.195; p = 0.026) in stroke patients (Table 3).

Table 3. Multiple linear regression analysis of hand grip strength with variables in stroke patients.

| Variables                  | Non-Paretic Arm |          |          |          |          |          |
|----------------------------|-----------------|----------|----------|----------|----------|----------|
|                            | B               | Beta     | p-Value  | B        | Beta     | p-Value  |
| Age                        | −0.294          | −0.346   | <0.0001 *| −0.132   | −0.121   | 0.151    |
| Female a                   | −0.706          | −0.392   | <0.0001 *| −0.464   | −0.202   | 0.014    |
| BMI                        | −0.043          | −0.016   | 0.846    | 0.108    | 0.031    | 0.716    |
| mRS                        | −2.707          | −0.404   | <0.0001 *| −5.382   | −0.627   | <0.0001 *|
| CAT (U/L)                  | −0.002          | −0.021   | 0.784    | 0.012    | −0.095   | 0.241    |
| SOD (U/L)                  | 0.000           | −0.115   | 0.191    | 0.000    | −0.116   | 0.207    |
| Hydrogen peroxide (µM)     | 0.121           | 0.092    | 0.272    | 0.329    | 0.195    | 0.026    |
| MDA (µM)                   | −0.251          | −0.101   | 0.202    | 0.042    | 0.013    | 0.872    |
| TNF-α (pg/mL)              | 0.009           | 0.114    | 0.189    | 0.005    | 0.052    | 0.565    |
| IL-6 (pg/mL)               | −0.001          | −0.014   | 0.869    | 0.000    | 0.003    | 0.972    |

* Males and females were assigned values of 0 and 1, respectively. The p-values determined by the linear regression were adjusted for age, gender, body mass index (BMI), modified Rankin Scale (mRS), catalase (CAT), superoxide dismutase (SOD), hydrogen peroxide, malondialdehyde (MDA), tumor necrosis factor (TNF)-α, and interleukin (IL)-6. * p < 0.05.

3.4. The Impact of Serum MDA on the Risk of Low HGS in Non-Paretic Limbs of Stroke Patients

Multiple logistic regression analysis was performed to identify for factor-independent associations of age, gender, BMI, mRS, CAT, SOD, hydrogen peroxide, MDA, TNF-α, and IL-6 with low HGS in non-paretic limbs. The multivariate analysis showed that older age (odds ratio (OR): 1.131; 95% CI: 1.053 to 1.097), higher mRS (OR: 3.357; 95% CI: 1.678 to 6.714), and MDA (OR: 1.280; 95% CI: 1.024 to 1.600) significantly increased the risk of low HGS in the non-paretic limbs of stroke patients (Table 4).

Table 4. Multivariate logistic regression analysis determining variables associated with low hand grip strength risk in stroke patients.

| Variables                  | B     | S.E.   | Adjusted Odds Ratio | 95% Confidence Interval | Adjusted p-Value |
|----------------------------|-------|--------|----------------------|-------------------------|-----------------|
| Age a                      | 0.123 | 0.036  | 1.131                | 1.053, 1.097             | 0.001 *         |
| Female a                   | 0.276 | 0.673  | 2.194                | 1.903, 2.545             | 0.243           |
| BMI                        | 0.043 | 0.673  | 1.044                | 0.861, 1.266             | 0.663           |
| mRS                        | 1.211 | 0.354  | 3.357                | 1.678, 6.714             | 0.001 *         |
| CAT (U/L)                  | 0.003 | 0.004  | 1.003                | 0.996, 1.010             | 0.427           |
| SOD (U/L)                  | 0.000 | 0.000  | 1.000                | 1.000, 1.001             | 0.112           |
| Hydrogen peroxide (µM)     | −0.073| 0.048  | 0.929                | 0.846, 1.021             | 0.127           |
| MDA (µM)                   | 0.274 | 0.119  | 1.280                | 1.024, 1.600             | 0.030 *         |
| TNF-α (pg/mL)              | 0.001 | 0.002  | 1.001                | 0.997, 1.004             | 0.802           |
| IL-6 (pg/mL)               | 0.000 | 0.002  | 1000                 | 0.996, 1.003             | 0.825           |

* Males and females were assigned values of 0 and 1, respectively. The p-values by logistic regression are adjusted for age, gender, body mass index (BMI), modified Rankin Scale (mRS), catalase (CAT), superoxide dismutase (SOD), hydrogen peroxide, malondialdehyde (MDA), tumor necrosis factor (TNF)-α, and interleukin (IL)-6. * p < 0.05.
4. Discussion

The present study notably reported, for the first time, a positive association between hydrogen peroxide and HGS in paretic limbs. Moreover, age, mRS, and MDA levels were shown to be the risks of low HGS in non-paretic limbs of post-stroke patients.

We found no difference in the HSG of non-paretic limbs between stroke patients and controls. This is possibly due to the comparable degree of dependency and disability, as assessed by BI and mRS, respectively. A reduction of muscle strength, indicated by low HGS, could be caused by a loss of mitochondrial bioenergetics of the muscles during aging and disuse atrophy after stroke. This proposed pathophysiology was confirmed by a muscle pathology study in healthy older adults with absolute bedridden status [37,38]. High mRS was found to be a risk factor for low HGS in non-paretic limbs in post-stroke patients, which supports this finding. It was also suggested that lower neuronal metabolism in the diseased primary motor cortex possibly contributes to low HGS [39].

MDA is a lipid peroxide derived from the peroxidation of polyunsaturated fatty acids [40] that is significantly increased in the acute phase and persistently sustained in the late phase of stroke [41]. One study showed that the plasma lipid peroxide level was significantly increased over time when compared across subjects in acute, subacute, and chronic phases after stroke [42]. Similar to some studies, our study revealed significantly elevated serum MDA levels in post-stroke patients compared with controls [43,44]. Moreover, an elevated serum MDA level was found to be a significant risk factor for low HGS in the non-paretic limbs of stroke patients. A previous study revealed a negatively correlation between MDA and the musculoskeletal index, and MDA has been accepted as a potential early biomarker of sarcopenia in older adults [22]. Therefore, MDA could be used as a blood biomarker for early diagnosis of muscle strength and muscle wasting loss in post-stroke patients. The predominant source of MDA production in post-stroke patients remains unclear. However, increased lipid peroxide and MDA levels might be due to spontaneous reactive oxygen species (ROS) generation by peripheral phagocytes [42], extracellular production of hydrogen peroxide by paretic muscles during denervation [45], or associated comorbidities, e.g., diabetes, hypertension, and hyperlipidemia [46].

Oxidative stress/oxidative damage has a profound effect on stroke pathogenesis and recurrence [47] and has been used as a marker of improvement after exercise training in post-stroke patients [48]. Based on normal physiology, SOD plays a role in regulating ROS signaling functions with subsequent biological responses [45]. In contrast, during oxidative stress, SOD has a regulatory role whereby it scavenges superoxide anions by generating hydrogen peroxide, which is further converted into hydrogen peroxide by CAT and glutathione peroxidase [49]. In our study, stroke patients had significantly decreased SOD activity levels with a concomitant increase in CAT activity compared with that of controls. Exhaustion may decrease serum SOD activity following prolonged ROS generation during ischemic events [50] and skeletal muscle pathology [51]. A previous study suggested that increased plasma SOD activity occurs after dynamic resistance training in post-stroke patients [48]. Another study revealed that the concentration of CAT in hemolysates was significantly increased in stroke patients at a 3-month follow-up check [52]. Therefore, the high levels of CAT activity observed in our stroke population may have potentiated the antioxidant defense mechanism against the increased production of ROS. This finding is concomitant with our study results showing that hydrogen peroxide tended to be decreased in stroke patients compared with controls. Interestingly, the regression analysis showed that hydrogen peroxide was positively associated with HGS in the paretic limbs of stroke patients. This may be due to the requirement of physiological levels of hydrogen peroxide for maintaining normal contractile activity in skeletal muscles [45]. In a previous study, it was suggested that hydrogen peroxide levels are necessary to maintain static force production or strength in the paretic limbs of stroke patients. In addition, a short period of hydrogen peroxide exposure was found to increase sub-maximal muscle force generation [53]. Nevertheless, a previous study revealed that hydrogen peroxide exposure decreased muscle force by suppressing myosin cross-bridge formation [54].
TNF-α has been proposed as a key biomarker of muscle weakness because of the induction of oxidant production in the muscles, causing myofilament dysfunction [55]. Although TNF-α levels were found to be significantly increased in stroke patients compared with controls, a correlation with low HGS was not found in the current study. Oxidative stress/oxidative damage and inflammation are ongoing processes in the chronic stroke phase. Prolonged oxidative stress/oxidative damage and inflammatory reactions after stroke contribute to cachexia after stroke, as determined by body weight loss, declines in fat and lean mass, low HGS, and eventual low physical performance [26]. The increment of oxidative damage biomarkers like MDA may be associated with reduced muscle strength, possibly leading to muscle mass loss among post-stroke patients. Thus, we suggest that antioxidant treatment and increased physical activity may be useful for preventing muscle wasting in post-stroke patients.

The association of oxidative stress/oxidative damage/inflammatory biomarkers with low HGS in community post-stroke patients is first documented in the current study. However, the following limitations should be considered: (1) the small sample size and single-center study nature; (2) the missing data and, in particular, insufficient volume of blood samples for biomarker assessment, may have affected the interpretation of the reported findings; and (3) the specific cut-off values used to indicate low HGS in non-paretic limbs for post-stroke patients, which have not been systemically determined. We suggest that the future research should document the use of appropriate sources for oxidative stress/oxidative damage/inflammatory biomarker assessment, i.e., skeletal muscles, of paretic and/or non-paretic limbs, among stroke patients. Furthermore, the association of biomarkers of muscle wasting or sarcopenia after stroke should be scientifically addressed.

5. Conclusions

Our study reported that advanced age, high mRS, and high serum MDA levels are risk factors for low HGS in the non-paretic limbs of post-stroke patients. Due to the association of low HGS in the non-paretic limbs of post-stroke patients with subsequent muscle strength loss and muscle wasting, we suggest that the presence of the mentioned clinical characteristics and high MDA levels are potential predictors muscle weakness and wasting in post-stroke patients. Thus, treatments involving reduction of the oxidation product MDA and encouragement of daily physical activity may delay further progression of muscle wasting in post-stroke patients.

Author Contributions: O.M., P.V., K.K., C.J., W.C. (Wanatsanan Chulrik), and P.P. performed data collection, laboratory investigation, and statistical analysis. O.M. and P.V. performed funding acquisition. O.M., P.S., and W.C. (Warangkana Chunglok) designed the study and wrote and revised the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Walailak University Fund (No. 12/2561 and WU61128) and The National Research Council of Thailand (No. 112/2561).

Acknowledgments: The authors acknowledge Wanida Limmun, Department of Mathematics and Statistics, School of Science, Walailak University for recommendations on statistical analysis.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kaji, R. Global burden of neurological diseases highlights stroke. Nat. Rev. Neurol. 2019, 15, 371–372. [CrossRef]
2. Min, K.B.; Min, J.Y. Health-related quality of life is associated with stroke deficits in older adults. Age Ageing 2015, 44, 700–704. [CrossRef]
3. Chang, S.H.; Francisco, G.E.; Zhou, P.; Rymer, W.Z.; Li, S. Spasticity, weakness, force variability, and sustained spontaneous motor unit discharges of resting spastic-paretic biceps brachii muscles in chronic stroke. Muscle Nerve 2013, 48, 85–92. [CrossRef]
4. Hunnicutt, J.L.; Gregory, C.M. Skeletal muscle changes following stroke: A systematic review and comparison to healthy individual. Top. Stroke Rehabil. 2017, 24, 463–471. [CrossRef]
5. Arasaki, K.; Igarashi, O.; Ichikawa, Y.; Machida, T.; Shirozu, I.; Hyodo, A.; Ushijima, R. Reduction in the motor unit number estimate (MUNE) after cerebral infarction. J. Neural. Sci. 2006, 250, 27–32. [PubMed]

6. Li, X.; Liu, J.; Li, S.; Wang, Y.C.; Zhou, P. Examination of hand muscle activation and motor unit indices derived from surface EMG in chronic stroke. IEEE Trans. Biomed. Eng. 2014, 61, 2891–2898. [PubMed]

7. Hu, X.; Suresh, A.K.; Rymer, W.Z.; Suresh, N.L. Altered motor unit discharge patterns in paretic muscles of stroke survivors assessed using surface electromyography. J. Neural Eng. 2016, 13, 046025. [PubMed]

8. Harris, M.L.; Polkey, M.I.; Bath, P.M.; Moxham, J. Quadriceps muscle weakness following acute hemiplegic stroke. Clin. Rehabil. 2001, 15, 274–281. [CrossRef] [PubMed]

9. Scherbakov, N.; Knops, M.; Ebner, N.; Valentova, M.; Sandek, A.; Grittnler, U.; Dahinden, P.; Hettwer, S.; Scheffold, J.C.; von Haehling, S.; et al. Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. J. Cachexia Sarcopenia Muscle 2016, 7, 60–67. [CrossRef]

10. Ekstrand, E.; Lexell, J.; Brogårdh, C. Grip strength is a representative measure of muscle weakness in the upper extremity after stroke. Top. Stroke Rehabil. 2016, 23, 400–405. [CrossRef]

11. Takahashi, J.; Nishiyama, T.; Matsushima, Y. Does grip strength on the unaffected side of patients with hemiparetic stroke reflect the strength of other ipsilateral muscles? J. Phys. Ther. Sci. 2017, 29, 64–66. [CrossRef]

12. Stock, R.; Thrane, G.; Askim, T.; Anke, A.; Mork, P.J. Development of grip strength during the first year after stroke. J. Rehabil. Med. 2019, 51, 248–256. [CrossRef]

13. Park, S.; Park, J.Y. Grip strength in post-stroke hemiplegia. J. Phys. Ther. Sci. 2016, 28, 677–679. [CrossRef] [PubMed]

14. Kim, N.S. Correlation between grip strength and pulmonary function and respiratory muscle strength in stroke patients over 50 years of age. J. Exerc. Rehabil. 2018, 14, 1017–1023. [CrossRef]

15. Yi, Y.; Shim, J.S.; Oh, B.M.; Seo, H.G. Grip Strength on the Unaffected Side as an Independent Predictor of Functional Improvement After Stroke. Am. J. Phys. Med. Rehabil. 2017, 96, 616–620. [CrossRef]

16. Sartor, L.C.A.; Luvizutto, G.J.; de Souza, J.T.; Silva Dalle Molle, E.R.; Modolo, G.P.; da Silva, T.R.; Prudente, R.A.; Ribeiro, P.W.; da Costa, R.D.M.; de Oliveira Antunes, L.C.; et al. Respiratory Function and Grip Strength in the Acute Phase of Stroke Are Associated with Stroke Severity and Disability at Hospital Discharge. Rehabil. Res. Pract. 2020, 2020, 1636540. [PubMed]

17. Chen, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Chou, M.Y.; Iijima, K.; Jang, H.C.; Kang, L.; Kim, M.; Kim, S.; et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J. Am. Med. Dir. Assoc. 2020, 21, 300–307. [CrossRef] [PubMed]

18. Chen, L.K.; Liu, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Bahyah, K.S.; Chou, M.Y.; Chen, L.Y.; Hsu, P.S.; Krairit, O.; et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. J. Am. Med. Dir. Assoc. 2014, 15, 95–101. [CrossRef] [PubMed]

19. Ryan, A.S.; Ivey, F.M.; Serra, M.C.; Hartstein, J.; Hafer-Macko, C.E. Sarcopenia and Physical Function in Middle-Aged and Older Stroke Survivors. Arch. Phys. Med. Rehabil. 2017, 98, 495–499. [CrossRef] [PubMed]

20. Yoshimura, Y.; Bise, T.; Shimazu, S.; Tanoue, M.; Tomioka, Y.; Araki, M.; Nishino, T.; Kuzuhaara, A.; Takatsuki, F. Effects of a leucine-enriched amino acid supplement on muscle mass, muscle strength, and physical function in post-stroke patients with sarcopenia: A randomized controlled trial. Nutrition 2019, 58, 1–6. [CrossRef]

21. Scherbakov, N.; von Haehling, S.; Anker, S.D.; Dirnagl, U.; Doehner, W. Stroke induced Sarcopenia: Muscle wasting and disability after stroke. Int. J. Cardiol. 2013, 170, 2, 9–94. [CrossRef]

22. Coto Montes, A.; Boga, J.A.; Bermejo Millo, C.; Rubio Gonzalez, A.; Potes Ochoa, Y.; Vega Naredo, I.; Martinez Reig, M.; Romero Rizos, L.; Sánchez Jurado, P.M.; Solano, J.J.; et al. Potential early biomarkers of sarcopenia among independent older adults. Maturitas 2017, 104, 117–122. [CrossRef] [PubMed]

23. Bian, A.L.; Hu, H.Y.; Rong, Y.D.; Wang, J.; Wang, J.X.; Zhou, X.Z. A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α. Eur. J. Med. Res. 2017, 22, 25. [CrossRef] [PubMed]

24. Can, B.; Kara, O.; Kizilarslanoglu, M.C.; Arik, G.; Ayçicek, G.S.; Sumer, F.; Civelek, R.; Demirtas, C.; Ulger, Z. Serum markers of inflammation and oxidative stress inarcopenia. Aging Clin. Exp. Res. 2017, 29, 745–752. [CrossRef]
25. Naritomi, H.; Moriwaki, H.; Metoki, N.; Nishimura, H.; Higashi, Y.; Yamamoto, Y.; Yuasa, H.; Oe, H.; Tanaka, K.; Saito, K.; et al. MARVELOUS (Muscular Atrophy Restraint with Vigilant Edaravone Long-term Use after Stroke) Study Group. Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: A randomized controlled pilot study. Version 2. Drugs R D 2010, 10, 155–163. [CrossRef]

26. Scherbakov, N.; Pietrock, C.; Sandek, A.; Ebner, N.; Valentova, M.; Springer, J.; Scheffold, J.C.; von Haehling, S.; Anke, S.D.; Norman, K.; et al. Body weight changes and incidence of cachexia after stroke. J. Cachexia Sarcopenia Muscle. 2019, 10, 611–620. [CrossRef] [PubMed]

27. Hafer-Macko, C.E.; Yu, S.; Ryan, A.S.; Ivey, F.M.; Macko, R.F. Elevated tumor necrosis factor-alpha in skeletal muscle after stroke. Stroke 2005, 36, 2021–2023. [CrossRef]

28. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363, 157–163. [CrossRef]

29. Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; ESC Scientific Document Group; et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018, 39, 3021–3104. [CrossRef]

30. Expert Dyslipidemia Panel; Grundy, S.M. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. J. Clin. Lipidol. 2017, 13, 561–565. [CrossRef]

31. AD Association. Classification and diagnosis of diabetes. Diabetes Care 2017, 40, S11–S24. [CrossRef] [PubMed]

32. Quinn, T.J.; Langhorne, P.; Stott, D.J. Barthel index for stroke trials: Development, properties, and application. Stroke 2011, 42, 1146–1151. [CrossRef] [PubMed]

33. Shah, S.; Vanclay, F.; Cooper, B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J. Clin. Epidemiol. 1989, 42, 703–709. [CrossRef]

34. Banks, J.L.; Marotta, C.A. Outcomes validity and reliability of the modified Rankin scale: Implications for stroke clinical trials: A literature review and synthesis. Stroke 2007, 38, 1091–1096. [CrossRef] [PubMed]

35. Roberts, H.C.; Denison, H.J.; Martin, H.J.; Patel, H.P.; Syddall, H.; Cooper, C.; Sayer, A.A. A review of the measurement of grip strength in clinical and epidemiological studies: Towards a standardised approach. Age Ageing 2011, 40, 423–429. [CrossRef]

36. Ohkawa, H.; Orishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351–358. [CrossRef]

37. Larkin, L.M.; Davis, C.S.; Sims-Robinson, C.; Kostrominova, T.Y.; Van Remmen, H.; Richardson, A.; Feldman, E.L.; Brooks, S.V. Skeletal muscle weakness due to deficiency of CuZn-superoxide dismutase is associated with loss of functional innervation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301, R1400–R1407. [CrossRef]

38. Trevino, M.B.; Zhang, X.; Standley, R.A.; Wang, M.; Han, X.; Reis, F.C.G.; Periasamy, M.; Yu, G.; Kelly, D.P.; Goodpaster, B.H.; et al. Loss of mitochondrial energetics is associated with poor recovery of muscle function but not mass following disuse atrophy. Am. J. Physiol. Endocrinol. Metab. 2019, 317, E899–E910. [CrossRef]

39. Cirstea, C.M.; Savage, C.R.; Nudo, R.J.; Cohen, L.G.; Yeh, H.W.; Choi, I.Y.; Lee, P.; Craciunas, S.C.; Popescu, E.A.; Bani-Ahmed, A.; et al. Handgrip-Related Activation in the Primary Motor Cortex Relates to Underlying Neuronal Metabolism After Stroke. Neurorehabil. Neural Repair. 2014, 28, 433–442. [CrossRef]

40. Barrera, G.; Pizzimenti, S.; Daga, M.; Dianzani, C.; Arcaro, A.; Cetrangolo, G.P.; Giordano, G.; Cucci, M.A.; Graf, M.; Gentile, F. Lipid Peroxidation-Derived Aldehydes, 4-Hydroxynonenal and Malondialdehyde in Aging-Related Disorders. Antioxidants 2018, 7, 102. [CrossRef]

41. Nakane, H.; Kamouchi, M.; Hata, J.; Ibayashi, S.; Kusuda, K.; Omae, T.; Nagao, T.; Ago, T.; Kitazono, T. EMINENT Study Investigators. Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: The EMINENT study. Intern. Med. 2015, 54, 573–577. [CrossRef] [PubMed]

42. Alexandrova, M.L.; Bochev, P.G.; Markova, V.I.; Bechev, B.G.; Popova, M.A.; Danovska, M.P.; Simeonova, V.K. Oxidative stress in the chronic phase after stroke. Redox Rep. 2003, 8, 169–176. [CrossRef] [PubMed]

43. Bir, L.S.; Demir, S.; Rota, S.; Köseoğlu, M. Increased serum malondialdehyde levels in chronic stage of ischemic stroke. Tohoku J. Exp. Med. 2006, 208, 33–39. [CrossRef]
44. Corrêa Mde, C.; Maldonado, P.; da Rosa, C.S.; Lunke, G.; Lunke, D.S.; Kaizer, R.R.; Ahmed, M.; Morsch, V.M.; Pereira, M.E.; Schetinger, M.R. Oxidative stress and erythrocyte acetylcholinesterase (AChE) in hypertensive and ischemic patients of both acute and chronic stages. *Biomed. Pharmacother.* **2008**, *62*, 317–324. [CrossRef] [PubMed]

45. Jackson, M.J.; McArdle, A. Role of reactive oxygen species in age-related neuromuscular deficits. *J. Physiol.* **2016**, *15*, 1979–1988. [CrossRef] [PubMed]

46. Cheng, Y.C.; Sheen, J.M.; Hu, W.L.; Hung, Y.C. Polyphenols and Oxidative Stress in Atherosclerosis-Related Ischemic Heart Disease and Stroke. *Oxid. Med. Cell. Longev.* **2017**, *2017*, 8526438. [CrossRef] [PubMed]

47. Alexandrova, M.L.; Bochev, P. Oxidative stress during the chronic phase after stroke. *Free Radic. Biol. Med.* **2005**, *39*, 297–316. [CrossRef] [PubMed]

48. Gambassi, B.B.; Coelho-Junior, H.J.; Paixão Dos Santos, C.; de Oliveira Gonçalves, I.; Mostarda, C.T.; Marzetti, E.; Sotão, S.S.; Uchida, M.C.; De Angelis, K.; Rodrigues, B. Dynamic Resistance Training Improves Cardiac Autonomic Modulation and Oxidative Stress Parameters in Chronic Stroke Survivors: A Randomized Controlled Trial. *Oxid. Med. Cell. Longev.* **2019**, *2019*, 5382843.

49. Wang, Y.; Branicky, R.; Noë, A.; Hekimi, S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. *J. Cell Biol.* **2018**, *217*, 1915–1928. [CrossRef]

50. Singh, P.; Mann, K.A.; Mangat, H.K.; Kaur, G. Prolonged glutamate excitotoxicity: Effects on mitochondrial antioxidants and antioxidant enzymes. *Mol. Cell Biochem.* **2003**, *243*, 139–145. [CrossRef][PubMed]

51. Garnham, J.O.; Roberts, L.D.; Espino-Gonzalez, E.; Whitehead, A.; Swoboda, P.P.; Koshy, A.; Gierula, J.; Paton, M.F.; Cubbon, R.M.; Kearney, M.T.; et al. Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology. *J. Cachexia Sarcopenia Muscle* **2020**, *11*, 394–404. [CrossRef]

52. Žitanová, I.; Šiariková, K.; Kollár, B.; Chomová, M.; Pazderová, P.; Andrezálová, L.; Ježovičová, M.; Koňariková, K.; Labertová, L.; Krivošiková, Z.; et al. Oxidative Stress Markers and Their Dynamic Changes in Patients after Acute Ischemic Stroke. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 9761697. [CrossRef]

53. Cheng, A.J.; Yamada, T.; Russier, D.E.; Andersson, D.C., Westerblad, H.; Lanner, J.T. Reactive oxygen/nitrogen species and contractile function in skeletal muscle during fatigue and recovery. *J. Physiol.* **2016**, *594*, 5149–5160. [CrossRef][PubMed]

54. Kochubei, P.V.; Kopylova, G.V.; Shchepkin, D.V.; Bershitskii, S.Y. Hydrogen Peroxide Treatment of Muscle Fibres Inhibits the Formation of Myosin Cross-Bridges. *Bull. Exp. Biol. Med.* **2018**, *166*, 183–187. [CrossRef]

55. Stasko, S.A.; Hardin, B.J.; Smith, J.D.; Moylan, J.S.; Reid, M.B. TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle. *J. Appl. Physiol.* **2013**, *114*, 1629–1636. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).